Bangalore-based TCG Lifesciences has been a preferred provider of discovery chemistry services for Pfizer since 2005. Under the new agreement, the CRO will provide services in other areas, including the synthesis of monomer and templates, medicinal chemistry and parallel medicinal chemistry. Neither company released the financial terms of the deal, but, according to published reports, it will extend for more than two years with possible milestone payments paid to TCG along the way.
"We are excited at the prospect of supporting Pfizer across the drug discovery and development value chain in an integrated manner,” said TCG’s managing director Swapan Bhattacharya. “This development is of great importance for us as it signifies our competences in providing innovation based integrated research services from early stage discovery to kilo scale production of first in man material".